RVMD
Revolution Medicines develops drug candidates targeting RAS and other oncology-related pathways. The pipeline is in preclinical and clinical development stages, with efforts focused on discovering and advancing product candidates through regulatory approval processes. The organization is pursuing multiple indications and relies on collaborations and licensing arrangements to support its research and development operations.
Pipeline
Pyrimidine analog chemotherapy that inhibits thymidylate synthase, blocking DNA synthesis. Foundational in colorectal, breast, and head/neck cancers (FOLFOX, FOLFIRI regimens).
Oral first-in-class pan-mutant RAS(ON) inhibitor (RMC-6236, Revolution Medicines) that binds the active GTP-bound state of multiple KRAS mutants. Under investigation in pancreatic, NSCLC, and colorectal cancer.
Taxane chemotherapy that stabilizes microtubules and arrests mitosis. Used in breast, prostate, NSCLC, head and neck, and gastric cancers.
Pyrimidine nucleoside analog chemotherapy that incorporates into DNA and inhibits ribonucleotide reductase. First-line in pancreatic cancer; used in lung, breast, and bladder cancers.
Topoisomerase I inhibitor chemotherapy that prevents DNA religation. Used in colorectal cancer (FOLFIRI) and other GI cancers.
Reduced folate used to rescue normal cells from methotrexate toxicity and to potentiate 5-FU activity (FOLFOX, FOLFIRI). Not a primary anticancer agent.
Albumin-bound paclitaxel (Abraxane) with improved delivery and reduced solvent toxicity. Used in metastatic breast cancer, NSCLC, and pancreatic adenocarcinoma.
Third-generation platinum chemotherapy that forms DNA adducts. Backbone in colorectal cancer (FOLFOX) and other GI malignancies.
Daraxonrasib (RMC-6236, Revolution Medicines): pan-mutant RAS(ON) inhibitor binding active GTP-bound KRAS. Phase 3 in pancreatic and NSCLC.
Anti-VEGF-A monoclonal antibody (Avastin) that inhibits tumor angiogenesis. Approved for colorectal, ovarian, breast, glioblastoma, and other solid tumors.
Platinum-based chemotherapy that forms DNA crosslinks, inducing apoptosis in cancer cells. Standard of care across many solid tumors including NSCLC, ovarian, breast, bladder, and biliary cancers.
Chimeric anti-EGFR monoclonal antibody (Erbitux) that blocks EGFR signaling and triggers ADCC. Approved in metastatic colorectal cancer (KRAS wild-type) and head and neck cancer.
Platinum-based chemotherapy that forms DNA crosslinks. Foundational cytotoxic agent used across testicular, bladder, ovarian, head and neck, and lung cancers.
Oral KRAS G12C(ON) inhibitor (RMC-6291, Revolution Medicines) targeting the active GTP-bound conformation. Under investigation in KRAS G12C-mutant solid tumors.
Anti-PD-1 monoclonal antibody (Keytruda) that blocks the PD-1 checkpoint, restoring anti-tumor immune response. FDA-approved across many cancers including NSCLC, melanoma, and gastroesophageal cancer.
Multi-targeted antifolate chemotherapy used in non-squamous NSCLC and mesothelioma, typically combined with platinum agents.
Oral KRAS G12D(ON) inhibitor (Revolution Medicines) targeting the active GTP-bound G12D mutant. Under investigation in pancreatic and colorectal cancer.
Catalyst Calendar
“The Company continues to anticipate initiating the RASolute 302 study in the second half of 2024.”
“On April 13, 2026, Revolution Medicines, Inc. (the "Company") shared topline results from its global, randomized, controlled Phase 3 RASolute 302 clinical trial evaluating daraxonrasib in patients with metastatic pancreatic ductal adenocarcinoma ("PDAC") who had been previously treated.”